Target intelligence / Profile preview

High mobility group nucleosomal binding domain 2 pseudogene 13 (HMGN2P13)

Target: HMGN2P13
Molecular classification: Pseudogene, Non-coding RNA (potential)

Overview

High mobility group nucleosomal binding domain 2 pseudogene 13 (HMGN2P13) is a human pseudogene related to the high mobility group nucleosomal binding domain protein family. Pseudogenes are non-functional genomic elements with high sequence homology to functional genes but lack protein-coding capacity[4]. While some pseudogenes influence the expression of their parental genes via RNA-mediated mechanisms, there are no data suggesting that HMGN2P13 has a functional impact on cellular processes, disease, or therapy. It is not considered a therapeutic target or a biomarker. Its biological and clinical significance, if any, remains to be determined.

Mechanism of action

None. As a noncoding pseudogene, it lacks a protein product to which drugs can bind, and no drugs are known to interact with this pseudogene.

Biological functions

None directly known for HMGN2P13. In general, some pseudogenes have been shown to regulate their parental genes by acting as competing endogenous RNAs (ceRNAs) or miRNA sponges, but this has not been established for HMGN2P13 specifically.

Disease associations

None reported for HMGN2P13. In general, some pseudogenes affect cancer, metabolic disease, or other contexts by regulation of parental genes, but HMGN2P13-specific roles have not been described in the literature.

Safety considerations

None known or relevant for pseudogenes in general, and no data for HMGN2P13 specifically.

Biomarkers

None specific. Some pseudogenes are used as expression biomarkers in research, but there is no information supporting such a role for HMGN2P13.

Beyond the preview

Go deeper on High mobility group nucleosomal binding domain 2 pseudogene 13 (HMGN2P13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 13 (HMGN2P13).

Explore the full profile